


Agenda

- Q2 highlights
- Strategic update
- Business Unit performance
- Group financials
- 2022 outlook
- Q&A

Disclaimer

This presentation contains forward-looking statements including projections on future financial results. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the outlook. Furthermore, some of these expectations are based on assumptions regarding future events, which may prove incorrect. Please refer to the risk management section on page 47-49 of the Annual Report 2021.




Q2 highlights

- Transformative divestment of infrastructure business announced
- Consolidation of global delivery capabilities on track
- Slower-than-expected sales and continued impact of renegotiated infrastructure agreement with NNG
- Major contract with Danmarks Nationalbank

Revenue and operating margin



Order backlog





Strategic update

TRANSFORMATION

Divestment sharpens focus as specialized IT services provider in growth areas

PROFITABILITY

Continued cost reductions including consolidation of global delivery capabilities

STRATEGY

Increase growth and profitability Two core business units Continued focus on M&A

NEXT STEPS

Carveout progressing as planned Clarification and new guidance Subject to approvals


BACKLOG

Continued growth based on signing of large contracts and key renewals



Life Sciences Solutions (LSS)

- 33% growth mainly driven by acquisitions
- Cancelled project continued to impact organic growth and margins
- Capacity utilization and gross margin improved from Q1
- Repeated solution sales and strong traction in Regulatory Affairs and International Pharma Production




Order backlog






Cloud & Digital Solutions (CDS)

- Revenue and margins impacted by lower utilization and higher costs
- Lower Public customer sales and impact of postponed ERP project
- Measures initiated to adjust capacity with effect in H2
- Several contract extensions and wins, including four-year contract with Danish health authorities










Hybrid Cloud Solutions (HCS)

- Continued impact of renegotiated NNG infrastructure agreement
- Measures intiated to increase capacity utilization
- Automation efforts and relocation of outsourcing to the Philippines
- Six-year contract with Danmarks Nationalbank worth DKK ~1 billion

Revenue and gross margin




Order backlog





Group financials Q2 and 6M 2022

DKKm	Q2-22	Q2-21	6M-22	6M-21	FY-21
Revenue	723	710	1,424	1,441	2,877
Revenue growth	1.8%	1.3%	-1.2%	1.3%	1.7%
Gross profit	66	105	132	225	420
Sales and marketing costs	40	35	78	73	145
Administrative expenses	37	34	74	68	133
Operating profit before special items	-11	36	-20	84	142
Operating margin before special items	-1.5%	5.1%	-1.4%	5.8%	4.9%
Special items	36	63	71	69	153
Operating profit/loss	-47	-27	-91	15	-11
Net financials	-4	-11	-5	-15	-14
Net profit/loss	-47	-30	-80	1	-7
Free cash flow	-19	150	-256	64	11



2022 outlook suspended

- IO business to be reclassified as 'discontinued activities'
- Impact on financial reporting is being settled
- Temporary suspension maintained
- 2022 guidance to be introduced in H2
- Strengthen revenue and profitability of continuing activities from 2023



Closing remarks

Significant strategic moves initiated and progressed in Q2



Continued order backlog growth with wins across Business Units



Settling impact of divestment on continuing business








Q&A





Contact information

Pernille Fabricius CFO
PNFA@nnit.com



Financial calendar 2022 Interim report Q3

November 2, 2022



We make a mark



Appendix: Life Sciences Solutions

DKKm	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Revenue	222	198	199	191	166
Life Sciences (excl. NGG)	201	170	175	166	145
- Life Sciences (Int.)	192	163	167	160	137
- Life Sciences (DK)	9	7	8	6	8
Novo Nordisk Group	21	28	24	24	20
Public	0	0	0	1	1
Production costs	180	170	150	145	125
Gross profit	42	28	49	46	41
Gross profit margin	19.1%	14.0%	24.9%	24.0%	24.8%
Order backlog	674	541	408	684	611



Appendix: Cloud & Digital Solutions

DKKm	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Revenue	206	213	225	199	213
Life Sciences (excl. NGG)	36	35	40	31	35
- Life Sciences (Int.)	12	11	17	12	16
- Life Sciences (DK)	23	24	23	19	19
Novo Nordisk Group	23	23	23	21	22
Enterprise	103	106	111	101	101
Public	37	40	41	38	47
Finance	9	9	10	8	8
Production costs	189	186	184	174	182
Gross profit	17	27	41	25	31
Gross profit margin	9.1%	12.6%	18.3%	12.4%	14.5%
Order backlog	756	656	597	822	768



Appendix: Hybrid Cloud Solutions

DKKm	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Revenue	295	290	314	308	331
Life Sciences (excl. NGG)	37	39	45	48	53
- Life Sciences (Int.)	10	14	15	15	12
- Life Sciences (DK)	27	25	30	33	41
Novo Nordisk Group	90	89	107	98	108
Enterprise	86	81	83	81	85
Public	22	24	25	25	25
Finance	60	57	54	56	60
Production costs	288	280	299	290	298
Gross profit	7	10	15	18	33
Gross profit margin	2.5%	3.4%	4.7%	5.9%	9.9%
Order backlog	1,142	997	1,012	1,284	1,264

